Differential expression of genes influencing mitotic processes in cord blood mononuclear cells after a pre-conceptional micronutrient-based randomized controlled trial: Pune Rural Intervention in Young Adolescents (PRIYA)

Satyajeet P. Khare^{1,2#}, Ayush Madhok^{1#}, Indumathi Patta¹, Krishna K. Sukla³, Vipul V. Wagh², Pooja S. Kunte³, Deepa Raut³, Dattatrey Bhat³, Kalyanaraman Kumaran⁴, Caroline Fall⁴, Utpal S. Tatu⁵, Giriraj R. Chandak⁶, Chittaranjan Yajnik^{3*}, Sanjeev Galande^{1, 7*}

1. Indian Institute of Science Education and Research (IISER), Pune, Pashan, Pune, Maharashtra 411008, India

2. Symbiosis School of Biological Sciences (SSBS), Symbiosis International (Deemed University), Lavale, Pune, Maharashtra, 412115, India

3. King Edward Memorial Hospital Research Centre, Pune, Maharashtra, 411022, India

4. Medical Research Council Lifecourse Epidemiology Unit, Southampton, UK

5. Indian Institute of Science (IISc), Bangalore, India

6. Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India

7. Department of Life Sciences, Shiv Nadar University, Gautam Buddha Nagar, Uttar Pradesh, 201314, India.

[#] These authors contributed equally

*** For correspondence:**

csyajnik@gmail.com

sanjeev@iiserpune.ac.in

Keywords: Vitamin B12 and micronutrients, randomized controlled trial, cord blood mononuclear cells, gene expression profiling, cell cycle, mitotic processes.

1 Abstract:

2 In the Pune Maternal Nutrition Study, low maternal vitamin B12 and high folate concentrations
3 during pregnancy predicted adiposity and insulin resistance (diabesity) in the children. Based on
4 these findings, we designed an RCT (PRIYA) to provide these nutrients pre-conceptionally to reduce
5 diabesity in the offspring. The interventions included: 1) vitamin B12+multi-micronutrients and
6 protein supplement (B12+MMN), 2) vitamin B12 alone, and 3) placebo. A total of 149 women
7 became pregnant and delivered in the trial. We report results of RNA sequencing in the cord-blood
8 mononuclear cells in 88 deliveries. Gene expression analysis revealed 20 differentially expressed
9 genes (FDR <0.1, a discovery threshold) between the B12+MMN and placebo groups. The enriched
10 biological processes included: chromosome segregation, nuclear division and organelle fission. A cell
11 cycle checkpoint gene *Claspin* (*CLSPN*) was expressed less in the B12+MMN group but proliferation
12 markers did not differ. No difference was observed between the B12 alone and placebo groups. The
13 B-complex vitamins are essential for nucleotide synthesis and generation of S-Adenosyl Methionine,
14 a universal cellular methyl donor and thereby may contribute to the regulation of gene expression.
15 Vitamins A and D, and zinc in MMN may also influence gene expression. We propose that the multi-
16 micronutrient intervention influenced rate of progression of specific phases of cell cycle without
17 affecting proliferation. Vitamin B12 alone was not sufficient.

18 We highlight a novel molecular mechanism for the effect of multi-micronutrients during fetal
19 development, and a plausible mechanism for intergenerational nutritional programming. Follow up
20 studies will help understand their implications on the future phenotype.

21 Introduction:

22 The Developmental Origins of Health and Disease (DOHaD) paradigm proposes that the environment
23 during crucial stages of development modifies gene expression through various epigenetic changes
24 which permanently affect the structure and function of an organism (Heindel and Vandenberg,
25 2015). The DOHaD paradigm was derived from Prof. David Barker's demonstration that lower birth
26 weight (indicative of poor fetal nutrition) was a risk factor for future diabetes and cardiovascular
27 disease (Barker et al., 1989) and suggests a preventable susceptibility factor for these conditions.

28 Methylation of DNA and histones are two epigenetic modifications which influence gene expression
29 (Cedar and Bergman, 2009). Methylation is affected by dietary nutrients which provide or generate
30 methyl groups for cellular metabolism (Switzeny et al., 2012; Kok et al., 2015). These include
31 vitamins B12, folate, B2, B6, choline, betaine, and proteins (Zeisel, 2017). Vitamins A and D are also
32 known to influence gene expression through their interaction with the nuclear receptors (Berry et
33 al., 2011; Pasing et al., 2017). Deficiency of these nutrients in the diet of a pregnant mother
34 manifests in various developmental defects (neural tube defects, midline congenital defects etc.)
35 and fetal growth abnormalities (growth restriction) (Gernand et al., 2016). Deficiencies of these
36 nutrients in early life are also associated with an increased risk of non-communicable diseases in
37 later life (Deshmukh et al., 2013).

38 The Pune Maternal Nutrition Study (PMNS) is a community based pre-conceptional birth cohort
39 started in 1993. We found that two thirds of the pregnant mothers had low vitamin B12 status but
40 folate status was adequate in the majority (Yajnik et al., 2007). Low maternal B12 status coupled
41 with normal to high folate status was associated with increased diabesity (adiposity and insulin

resistance) in the children (Yajnik et al., 2007). Vitamin D deficiency in the mothers was associated with increased adiposity in the children (Wagh et al., 2020). These findings led to the Pune Rural Intervention in Young Adolescents (PRIYA) trial (ISRCTN 32921044 and CTRI 2012/12/003212) (Kumaran et al., 2017). The trial provided vitamin B12 and other micronutrients along with milk proteins to the women in the PMNS cohort with a view to reduce the risk of diabetes in their offspring. The PRIYA trial started from the pre-conceptional stage and continued until delivery of the offspring. The trial provided an opportunity to study the effects of maternal micronutrient supplementation on changes in DNA methylation, transcriptome, proteome and metabolome in the cord blood of the newborn. In this paper, we report our early findings of cord blood transcriptome analysis in the PRIYA trial.

Materials and Methods:

The PRIYA trial

PRIYA is a randomized, double blind, placebo-controlled trial in adolescent participants of the PMNS (Figure 1). The rationale and methods of the PRIYA trial are described previously (Kumaran et al., 2017). In short, 690 adolescent participants were screened for B12 levels to rule out severe vitamin B12 deficiency (plasma vitamin B12 concentration <100 pmol/L) or severe anaemia (blood hemoglobin concentration <70 gm/L) for ethical imperatives of a placebo controlled trial. Those with chronic medical conditions were also excluded. Eligible participants were randomised into 3 supplementation groups: 1) vitamin B12 (2 µg/day) along with multi-micronutrients as per UNIMMAP (World Health Organization, 1999), excluding folic acid and conforming to local regulatory requirements (Supplementary Table 1), 2) Placebo, 3) vitamin B12 (2 µg/day) alone. The multi-micronutrient group also received 20 gm of milk powder every day and all 3 groups received iron and folic acid as per Government of India approved dosage (60 mg elemental iron + 500 µg folic acid once a week before pregnancy and at least 100 tablets during pregnancy). The trial intervention was continued until delivery of the first live child.

Monthly supplementation was provided by local field staff, which was in regular touch with the participants. Marriages were recorded and the pregnancies were diagnosed by a urine pregnancy test. At 28-weeks' gestation, an obstetric consultation as well as blood tests were performed. The field staff monitored the pregnant women and helped transfer them for delivery at the KEM Hospital, Pune. Trained research staff attended the deliveries and collected cord blood samples as per a standardised protocol. Details of the delivery and baby's measurements were also recorded. A cord blood aliquot was transferred to RNeasy (QIAGEN, Germany) tubes and stored at -80°C till further processing.

Blood measurements

Plasma vitamin B12, holo-TC, folate, vitamin B6, and total homocysteine were measured at baseline (before starting the supplementation), 6-12 months after starting supplementation, at 28 weeks gestation, at delivery, and in the cord blood. Vitamin B2 was also measured at these time-points except at the baseline. Supplementary Table 2 describes the laboratory methods used for these measurements.

40

1 Statistical methods for clinical characteristics:

2 The data for maternal and neonatal clinical characteristics is represented as median (IQR). The
3 significance of difference between intervention groups was tested by Mann-Whitney test.

4 Isolation of cord blood mononuclear cells

5 Mononuclear cells from the cord blood were extracted after depleting RBCs from whole blood. In
6 brief, batches of frozen blood samples were thawed and diluted with one volume of phosphate
7 buffer saline supplemented with EDTA (2mM). One volume of RBC lysis buffer (Biolegend # 420301)
8 was added to the diluted samples and incubated for 5 minutes at RT. The tubes were centrifuged at
9 350 x g for 15 min at 4°C and the pellets were processed for RNA isolation.

10 RNA isolation, sequencing and data analysis

11 Cord blood mononuclear cells were subjected to RNA isolation using TriZol reagent (Invitrogen).
12 Quantitation of RNA was performed on Qubit 4 Fluorometer (Thermo Scientific #Q33238) using RNA
13 HS Kit (Thermo Scientific #Q32852). Libraries were prepared according to the manufacturer's
14 protocol (Illumina). Briefly, each sample was run on 2100 Bioanalyzer (Agilent #G2939BA) to check
15 its integrity. About 500 ng of total RNA from each sample was used to make libraries using TruSeq
16 Stranded mRNA Sample Prep Kit (Illumina #20020594). After final quantification and pooling, the
17 libraries were run on Illumina HiSeqX platform, with 150 nucleotides long paired end reads as the
18 output.

19 The raw sequence reads were aligned to the human genome (hg38, Gencode) (Frankish et al., 2019)
20 using HiSAT2 (Kim et al., 2019). The resulting BAM files were used to generate a count matrix using
21 featureCounts for known genes (Liao et al., 2014). The count matrix was used for differential
22 expression analysis using DESeq2 (Love et al., 2014). Since the samples were processed in batches,
23 the batch numbers were used as a covariate. The sex of the child was also used as a covariate. For
24 this discovery analysis we used a p-value adjusted to the FDR of 0.1 as a cut off. The fold change was
25 log transformed to the base 2 as per the convention. Significantly differentially expressed genes
26 were subjected to gene enrichment analysis using clusterProfiler (v3.14.3) (Yu et al., 2012).

27 Results:

28 Trial progress and clinical findings:

29 Six hundred and ninety adolescent participants in the PMNS were screened for inclusion in the PRIYA
30 trial (Figure 1). A total of 133 were excluded and 557 (266 girls, 291 boys, average age 17 years)
31 were randomized into 3 groups. A total of 182 girls married, 166 became pregnant and 149 delivered
32 in the study. Cord blood samples were available on 138 for gene expression analysis. This paper
33 reports transcriptome measurements on the first 88 cord blood samples (40 girls, 48 boys). These 88
34 pregnancies were comparable to the 50 who were not included in this study [with respect to
35 maternal age, body mass index (BMI), socio-economic status, and hemoglobin concentrations at 28
36 weeks gestation, $p > 0.05$].

37 The mothers were on average 21 years old and weighed 53.0 kgs with a BMI of 22.0 kg/m² at 28
38 weeks gestation (Table 1). Twenty-three mothers delivered by caesarean section. The average birth

1 weight of babies was 2.8 kg (11.3% were low birth weight i.e., <2.5 kg), 3.4% were born pre-term.
2 There was not significant difference in the birth size and pregnancy outcomes in the 3 intervention
3 groups.

4 At baseline (at 17 years of age) plasma vitamin B12 concentrations were low and 47.7% were B12
5 deficient (<150 pmol/L), only 1% were folate deficient (<7 nmol/L). Plasma homocysteine
6 concentrations were high, 91% had hyperhomocysteinemia (>15 µmol/L). B12, folate and
7 homocysteine concentrations were similar in the 3 intervention groups.

8 Figure 2 shows serial concentrations of vitamin B12, holo-TC ('active' B12), folate and homocysteine
9 during the trial. It can be seen that mothers in the two vitamin B12 supplemented groups had higher
10 vitamin B12 status compared to the placebo group after supplementation; and had lower
11 homocysteine concentrations. Levels of vitamin B2 and B6 were the highest in the B12+MMN group
12 after supplementation (Table 1). Maternal hemoglobin concentrations and other hematological
13 parameters were similar in the 3 groups.

14 Cord blood concentrations of vitamin B12, holo-TC and folate were higher than the maternal
15 concentrations. Although vitamin B12 and holo-TC were higher in the B12 supplemented groups, the
16 difference from the placebo group was not significant. (Figure 2, Table 1). Cord blood hemoglobin
17 concentration and red cell count were the highest in the group supplemented with B12 alone.

18 **RNA sequencing and differential gene expression analysis:**

19 Mononuclear cells from 88 cord blood samples were subjected to RNA sequencing. The quality of
20 sequencing was assessed using FastQC (v0.11.8). The quality of sequencing, and read duplication
21 levels were acceptable. Each sample generated approximately 50 million reads. The sample reads
22 generally aligned well with the reference genome. Out of the 88 samples, 7 samples showed low
23 alignment (alignment percentage < 70%) against the reference genome and were not considered for
24 the downstream analysis. Our final analysis was therefore, on 81 samples. All samples showed
25 comparable assignment to genes for generation of count matrix. The count matrix was used for
26 differential expression analysis.

27 Samples showed clear separation based on the sex of the child on principal component analysis
28 (PCA), however, no separation was observed based on laboratory batch or the intervention group
29 (data not shown). No difference in gene expression was observed in the intervention groups based
30 on gender. Differential expression analysis between the B12+MMN group and placebo resulted in
31 identification of 22 differentially expressed genes (Figure 3A) (FDR<0.1) of which 2 were
32 pseudogenes (*AC091057.1* and *DDX11L10*) and were not considered for further analysis (Table 2).
33 The log fold change ranged from -1.6 to 1.0.

34 To understand the gene-networking of the 20 differentially expression genes (DEGs), we performed
35 analysis using STRING (Szklarczyk et al., 2019). Eighteen of the 20 DEGs were involved in gene
36 networking while *PRSS21* and *FAM72C* were not part of the gene network and segregated separately
37 (Figure 3C). We used clusterProfiler to identify the top biological processes affected by the DEGs
38 (Figure 3B) (Yu et al., 2012). Participants supplemented with B12+MMN showed lower expression of
39 genes associated with mitotic processes such as chromosome segregation, nuclear division, and
40 organelle fission as compared to the placebo group. A cell cycle checkpoint gene, *Claspin* (*CLSPN*)

also showed lower expression in the intervention group (Figure 3D). However, cell proliferation markers such as Cyclin D1 (*CCND1*), *PCNA*, and Ki-67 (*MKI67*) did not show significant differences in gene expression (data not shown). No differentially expressed genes were observed between placebo and the B12 alone group; however, the 20 genes differentially expressed between B12+MMN and placebo were also under expressed in the B12 alone group (Table 2). No significantly differentially expressed genes were observed between the two active supplementation groups.

Discussion:

In the present study, we evaluated the effect of maternal pre-conceptional micronutrient intervention on the offspring's cord blood transcriptome. Vitamin B12+MMN intervention resulted in differential expression of 20 genes predominantly influencing mitotic processes such as chromosomal segregation, nuclear division, organelle fission, etc. when compared to placebo. Vitamin B12 alone did not significantly influence the transcriptome compared to the placebo group, though these 20 differentially expressed genes showed a similar trend (under-expression). This is, to our knowledge, the first report of changes in cord blood gene expression after a maternal nutritional intervention started from before conception. The majority of similar studies have only reported changes in DNA methylation (Fryer et al., 2011; Cooper et al., 2012; McKay et al., 2012; McCullough et al., 2016).

Nutritional deficiencies are common in the population of villages we have studied. Our intervention was based on our findings in earlier studies of substantial vitamin B12 deficiency in the participants and their parents. These villages are drought prone and residents have poor socio-economic status which would contribute to multiple micronutrient deficiencies and poor growth and development in babies. Our earlier observations showed that maternal vitamin B12 deficiency during pregnancy, coupled with higher levels of folate predicted higher adiposity and insulin resistance in the children (Yajnik et al., 2007). This prompted us to compare effects of supplementing vitamin B12 alone or in combination with other micronutrients on fetal outcomes. Our intervention showed a demonstrable increase in maternal vitamin B12, holo-TC, B2 and B6 levels in the multi-micronutrient group and of vitamin B12 and holo-TC in the B12 alone group. Though not measured, we would expect better nutrition of vitamins A, D and other micronutrients (vitamin E, Zn etc.) in the MMN group. An impressive fall in maternal homocysteine concentrations in both the active intervention groups (Figure 2) suggests better methylation status. These changes were evident within a few months of starting the supplementation and therefore ensured a better micronutrient status from the pre-conceptional stage and during pregnancy. The newborn in the B12+MMN group showed higher concentrations of vitamins B2 and B6, in addition to vitamin B12 and holo-TC, though only B6 was significantly different from placebo (Table 1). Despite significant differences in the maternal circulation, the lack of differences in some of these micronutrients may be due to: alterations in placental transport, differences in binding to carrier proteins, or differential utilisation by the baby (Whitfield et al., 2006; Lager and Powell, 2012). An inspection of the one-carbon (1-C) metabolic cycle (Supplementary Figure 1) and its regulation by B-complex vitamins suggests that babies of mothers who received vitamin B12+MMN would have a more comprehensive effect on purine and pyrimidine synthesis and therefore on DNA and RNA metabolism compared to those who received vitamin B12 alone. Reasons for higher hemoglobin concentration and red blood cell count in the vitamin B12 alone group are not immediately apparent.

1 A detailed analysis of our results suggested that of the 20 genes differentially expressed in the
2 vitamin B12+MMN group, 18 clustered in a network which regulates mitotic processes. The affected
3 biological processes include chromosome segregation, nuclear division, organelle fission, etc. These
4 results remind us of the changes described in the bone marrow of patients with pernicious anaemia
5 (a severe vitamin B12 deficiency condition which creates a functional folate deficiency and affects 1-
6 C metabolism in the direction of reduced methylation potential). The biochemical and morphological
7 changes in pernicious anaemia are suggestive of disturbed DNA synthesis and repair as well as
8 impaired cell division. A recent study on human astrocytes also showed that cobalamin (B12)
9 deficiency impairs DNA synthesis and prolongs G2/M transition leading to cell growth without cell
10 division (Rzepka et al., 2019).

11 We also investigated the expression of standard cell proliferation markers such as cyclin D1,
12 Minichromosome Maintenance Complex Component 2 (MCM2), Proliferating Cell Nuclear Antigen
13 (PCNA) and Ki-67 from the RNA-Seq data (Whitfield et al., 2006). None of these proliferation markers
14 showed a significant change in expression in any intervention group. However, *CLSPN*, an S-phase
15 checkpoint gene (Liu et al., 2006) showed lower expression in the B12+MMN group as compared to
16 placebo. We propose that a relative deficiency of micronutrients in the placebo group results in a
17 compensatory increase in the expression of genes involved in nucleic acid synthesis and cell division
18 triggered by hypomethylation of the relevant genes. However, micronutrient deficiency
19 compromises the supply of nucleotides for DNA synthesis and replication resulting in activation of
20 cell cycle checkpoint. On this background, it appears that genes related to DNA synthesis and cell
21 division were underexpressed in the B12+MMN group because the intervention led to increased
22 micronutrient levels and better methylation status which would promote methylation of the
23 relevant genes.

24 Our multi-micronutrient composition also included vitamins A and D, and zinc which are known to
25 affect gene expression and cell proliferation in specific tissues (MacDonald, 2000; Blomhoff, 2004;
26 Umar et al., 2018). We speculate that they could presumably contribute to some of our findings of
27 gene expression differences over and above the combined effect of B-complex vitamins in improving
28 cellular methylation potential.

29 **Strengths and Limitations:** One of the major strengths of our intervention study is that it was guided
30 by earlier nutritional observations in the same cohort. Supplementation in adolescents, much before
31 their marriage and pregnancy made it truly pre-conceptional and had the potential of influencing
32 peri-conceptional epigenetic reprogramming. We used 'physiological' doses of micronutrients, which
33 also makes it public health relevant. The limitations include that these preliminary results are on a
34 relatively small number of cord blood samples which will improve after results on the remaining
35 samples are available. The limited power could also have contributed to a lack of difference in the
36 cord blood measurements between placebo and B12+MMN groups or in body size measurements of
37 the babies in the three groups. Another limitation is that our transcriptomic measurements are
38 limited only to cord blood mononuclear cells which may not reflect changes in other tissues. The
39 specificity of tissue response and temporal changes with gestation can be investigated only in animal
40 models.

41 Our results provide perhaps the first human evidence for molecular effects of pre- and peri-
42 conceptional maternal B12+MMN intervention on cord blood. The intervention affected vital cellular

1 processes like cell cycle regulation and cell division during fetal development. These are plausible
 2 mechanisms for influencing intrauterine programming. Follow up studies in children will provide an
 3 opportunity to investigate the association of these novel alterations to programming of body size
 4 and composition, metabolism and neurocognitive function.

5 **Acknowledgments**

6 The work was supported by research grants from Department of Biotechnology (DBT), Government
 7 of India (CEIB-BT/PR12629/MED/97/364/2016) and Indian Council of Medical Research (ICMR) -
 8 MRC, UK grant (No.58/1/8/ICMR-MRC/2009-NCD-II). The authors thank Drs Ameya Sathe, Ankitha
 9 Shetty for their help in processing cord blood samples, Saurabh Pradhan for help with RNA-seq,
 10 Neelam Memane and Rajashree Kamat for laboratory assays, Aboli Bhalerao and Madhura
 11 Deshmukh, MSWs and ANMs for their help in the PRIYA study, Mrs. Pallavi Yajnik and Rasika Ladkat
 12 for administrative help. AM, IP, and VW thank CSIR-UGC , Government of India for research
 13 fellowships. SPK is also a beneficiary of a DST SERB SRG grant (SRG/2020/001414).

14 **Author contributions**

15 SPK and AM designed the experiments, performed the RNA-Seq analysis and wrote the manuscript.
 16 IP assisted in optimization of cell isolation and RNA preparation. KKS, VVW, PSK helped in data
 17 analysis and drafting the manuscript. CSY and CF designed the PRIYA trial. KK contributed to running
 18 the trial. GRC and UST contributed to the discussion and interpretations. DR and DB assisted in
 19 sample collection. SG designed the experiments. CSY and SG discussed and interpreted the results,
 20 supported the research, and wrote the manuscript. All authors read and approved the manuscript.

21

References:

- 1 Barker, D. J., Winter, P. D., Osmond, C., Margetts, B., and Simmonds, S. J. (1989). Weight in infancy
2 and death from ischaemic heart disease. *Lancet (London, England)* 2, 577–580.
3 doi:10.1016/S0140-6736(89)90710-1.
- 4
5
6 Berry, D. C., Jin, H., Majumdar, A., and Noy, N. (2011). Signaling by vitamin A and retinol-binding
7 protein regulates gene expression to inhibit insulin responses. *Proc. Natl. Acad. Sci. U. S. A.* 108,
8 4340–4345. doi:10.1073/PNAS.1011115108.
- 9 Blomhoff, H. K. (2004). Vitamin A regulates proliferation and apoptosis of human T- and B-cells.
10 *Biochem. Soc. Trans.* 32, 982–984. doi:10.1042/BST0320982.
- 11 Cedar, H., and Bergman, Y. (2009). Linking DNA methylation and histone modification: patterns and
12 paradigms. *Nat. Rev. Genet.* 10, 295–304. doi:10.1038/NGR2540.
- 13 Cooper, W., Khulan, B., Owens, S., Elks, C., Seidel, V., Prentice, A. M., et al. (2012). DNA methylation
14 profiling at imprinted loci after periconceptional micronutrient supplementation in humans:
15 results of a pilot randomized controlled trial. *FASEB J.* 26, 1782–1790. doi:10.1096/FJ.11-
16 192708.
- 17 Deshmukh, U., Katre, P., and Yajnik, C. S. (2013). Influence of maternal vitamin B12 and folate on
18 growth and insulin resistance in the offspring. *Nestle Nutr. Inst. Workshop Ser.* 74, 145–156.
19 doi:10.1159/000348463.
- 20 Frankish, A., Diekhans, M., Ferreira, A. M., Johnson, R., Jungreis, I., Loveland, J., et al. (2019).
21 GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Res.* 47,
22 D766–D773. doi:10.1093/nar/gky955.
- 23 Fryer, A. A., Emes, R. D., Ismail, K. M., Haworth, K. E., Mein, C., Carroll, W. D., et al. (2011).
24 Quantitative, high-resolution epigenetic profiling of CpG loci identifies associations with cord
25 blood plasma homocysteine and birth weight in humans. *Epigenetics* 6, 86–94.
26 doi:10.4161/EPI.6.1.13392.
- 27 Gernand, A. D., Schulze, K. J., Stewart, C. P., West, K. P., Jr, and Christian, P. (2016). Micronutrient
28 deficiencies in pregnancy worldwide: health effects and prevention. *Nat. Rev. Endocrinol.* 12,
29 274. doi:10.1038/NREND0.2016.37.
- 30 Heindel, J. J., and Vandenberg, L. N. (2015). Developmental Origins of Health and Disease: A
31 Paradigm for Understanding Disease Etiology and Prevention. *Curr. Opin. Pediatr.* 27, 248.
32 doi:10.1097/MOP.000000000000191.
- 33 Kim, D., Paggi, J. M., Park, C., Bennett, C., and Salzberg, S. L. (2019). Graph-based genome alignment
34 and genotyping with HISAT2 and HISAT-genotype. *Nat. Biotechnol.* 37, 907–915.
35 doi:10.1038/s41587-019-0201-4.
- 36 Kok, D. E., Dhonukshe-Rutten, R. A., Lute, C., Heil, S. G., Uitterlinden, A. G., van der Velde, N., et al.
37 (2015). The effects of long-term daily folic acid and vitamin B 12 supplementation on genome-
38 wide DNA methylation in elderly subjects. *Clin. Epigenetics* 2015 71 7, 1–14.
39 doi:10.1186/S13148-015-0154-5.
- 40 Kumaran, K., Yajnik, P., Lubree, H., Joglekar, C., Bhat, D., Katre, P., et al. (2017). The Pune Rural
41 Intervention in Young Adolescents (PRIYA) study: design and methods of a randomised
42 controlled trial. *BMC Nutr.* 3. doi:10.1186/S40795-017-0143-5.

- 1 Lager, S., and Powell, T. L. (2012). Regulation of nutrient transport across the placenta. *J. Pregnancy*
2 2012. doi:10.1155/2012/179827.
- 3 Liao, Y., Smyth, G. K., and Shi, W. (2014). FeatureCounts: An efficient general purpose program for
4 assigning sequence reads to genomic features. *Bioinformatics* 30, 923–930.
5 doi:10.1093/bioinformatics/btt656.
- 6 Liu, S., Bekker-Jensen, S., Mailand, N., Lukas, C., Bartek, J., and Lukas, J. (2006). Claspin Operates
7 Downstream of TopBP1 To Direct ATR Signaling towards Chk1 Activation. *Mol. Cell. Biol.* 26,
8 6056. doi:10.1128/MCB.00492-06.
- 9 Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion
10 for RNA-seq data with DESeq2. *Genome Biol.* 15, 550. doi:10.1186/s13059-014-0550-8.
- 11 MacDonald, R. S. (2000). The role of zinc in growth and cell proliferation. *J. Nutr.* 130.
12 doi:10.1093/JN/130.5.1500S.
- 13 McCullough, L. E., Miller, E. E., Mendez, M. A., Murtha, A. P., Murphy, S. K., and Hoyo, C. (2016).
14 Maternal B vitamins: effects on offspring weight and DNA methylation at genomically
15 imprinted domains. *Clin. Epigenetics* 8, 1–11. doi:10.1186/S13148-016-0174-9.
- 16 McKay, J. A., Groom, A., Potter, C., Coneyworth, L. J., Ford, D., Mathers, J. C., et al. (2012). Genetic
17 and non-genetic influences during pregnancy on infant global and site specific DNA
18 methylation: role for folate gene variants and vitamin B12. *PLoS One* 7.
19 doi:10.1371/JOURNAL.PONE.0033290.
- 20 Pasing, Y., Fenton, C. G., Jorde, R., and Paulssen, R. H. (2017). Changes in the human transcriptome
21 upon vitamin D supplementation. *J. Steroid Biochem. Mol. Biol.* 173, 93–99.
22 doi:10.1016/J.JSBMB.2017.03.016.
- 23 Rzepka, Z., Rok, J., Respondek, M., Pawlik, J., Beberok, A., Gryko, D., et al. (2019). Cobalamin
24 Deficiency: Effect on Homeostasis of Cultured Human Astrocytes. *Cells* 8.
25 doi:10.3390/CELLS8121505.
- 26 Switzeny, O. J., Müllner, E., Wagner, K. H., Brath, H., Aumüller, E., and Haslberger, A. G. (2012).
27 Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects.
28 *Clin. Epigenetics* 2012 41 4, 1–11. doi:10.1186/1868-7083-4-19.
- 29 Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., et al. (2019). STRING v11:
30 protein-protein association networks with increased coverage, supporting functional discovery
31 in genome-wide experimental datasets. *Nucleic Acids Res.* 47, D607–D613.
32 doi:10.1093/NAR/GKY1131.
- 33 Umar, M., Sastry, K., and Chouchane, A. (2018). Role of Vitamin D Beyond the Skeletal Function: A
34 Review of the Molecular and Clinical Studies. *Int. J. Mol. Sci.* 19, 1618.
35 doi:10.3390/IJMS19061618.
- 36 Wagh, R. H., Bawdekar, R. U., Alenaini, W., Fall, C. H. D., Thomas, E. L., Bell, J. D., et al. (2020).
37 Maternal Micronutrient Status in Pregnancy is Associated with Child’s Adiposity at 18yrs of age.
38 in (Journal of Developmental Origins of Health and Disease). doi:10.1017/S2040174419000643.
- 39 Whitfield, M. L., George, L. K., Grant, G. D., and Perou, C. M. (2006). Common markers of
40 proliferation. *Nat. Rev. Cancer* 6, 99–106. doi:10.1038/NRC1802.
- 41 World Health Organization (1999). Composition of a multi-micronutrient supplement to be used in

1 pilot programmes among pregnant women in developing countries: report of a United Nations
2 Children's Fund (UNICEF), World Health Organization (WHO) and United Nations University
3 workshop. Available at: <https://apps.who.int/iris/handle/10665/75358>.

4 Yajnik, C. S., Deshpande, S. S., Jackson, A. A., Refsum, H., Rao, S., Fisher, D. J., et al. (2007). Vitamin
5 B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the
6 Pune Maternal Nutrition Study. *Diabetologia* 51, 29–38. doi:10.1007/s00125-007-0793-y.

7 Yu, G., Wang, L. G., Han, Y., and He, Q. Y. (2012). clusterProfiler: an R package for comparing
8 biological themes among gene clusters. *OMICS* 16, 284–7. doi:10.1089/omi.2011.0118.

9 Zeisel, S. (2017). Choline, Other Methyl-Donors and Epigenetics. *Nutrients* 9.
10 doi:10.3390/NU9050445.

11 1.

1 Table 1: Comparison of clinical characteristics between study participants of 3 intervention groups

Maternal characteristics						
	B12+MMN group : Median (IQR) (N=29)	Placebo group : Median (IQR) (N=29)	B12 alone group : Median (IQR) (N=30)	P-value (B12+MMN Vs Placebo)	P-value (Placebo Vs B12 alone)	P-value (B12+MMN Vs B12 alone)
Anthropometry						
28 weeks gestation						
Age (Years)	21.2 (2.4)	21.3 (2.0)	21.1 (1.9)	0.578	0.773	0.781
BMI (kg/m ²)	21.5 (2.5)	21.7 (3.5)	20.8 (3.7)	0.975	0.176	0.080
Baseline (17 Years)						
Hemoglobin (g/dL)	12.8 (1.8)	12.7 (2.0)	12.7 (1.5)	0.474	0.738	0.268
Vitamin B12 (pmol/L)	160.0 (87.0)	147.0 (46.0)	148.5 (63.0)	0.131	0.439	0.544
Holo-TC (pmol/L)	13.0 (8.8)	10.1 (4.3)	10.2 (8.1)	0.096	0.934	0.145
Folate (nmol/L)	15.5 (13.5)	21.7 (11.2)	17.0 (14.6)	0.029	0.117	0.471
Homocysteine	21.0 (11.1)	24.2 (21.8)	22.8 (10.7)	0.539	0.328	0.897
Post-intervention (18 Years)						
Hemoglobin (g/dL)	12.0 (1.6)	12.0 (1.6)	11.7 (1.2)	1.000	0.219	0.179
Vitamin B12 (pmol/L)	262.0 (122.1)	161.9 (69.0)	272.5 (165.9)	0.000	0.000	0.246
Holo-TC (pmol/L)	23.6 (24.1)	8.9 (5.6)	28.8 (27.7)	0.000	0.000	0.295
Folate (nmol/L)	19.4 (11.9)	24.9 (19.8)	23.0 (14.8)	0.030	0.222	0.375
Homocysteine (μmol/L)	10.0 (4.5)	24.3 (19.8)	10.6 (4.1)	0.000	0.000	0.850
28 weeks gestation						
Hemoglobin (g/dL)	10.4 (1.7)	10.6 (1.6)	10.4 (1.9)	0.635	0.595	0.946
Vitamin B12 (pmol/L)	202.0 (121.0)	153.0 (109.0)	216.5 (180.5)	0.015	0.002	0.292
Holo-TC (pmol/L)	29.4 (29.8)	16.6 (14.6)	35.3 (50.2)	0.009	0.005	0.606
Folate (nmol/L)	42.1 (41.9)	45.6 (34.3)	48.3 (35.3)	0.497	0.850	0.655
Vitamin B2 (pmol/L)	240.0 (79.0)	226.0 (48.0)	224.0 (64.0)	0.351	0.586	0.202
Vitamin B6 (plp) (μg/ml)	4.9 (3.4)	3.6 (3.2)	3.2 (1.7)	0.010	0.720	0.000
Vitamin B6 (pyx) (μg/ml)	1.6 (1.2)	1.2 (0.7)	1.2 (0.5)	0.127	0.913	0.042
Homocysteine (μmoles/L)	6.6 (3.5)	6.6 (4.0)	6.2 (3.6)	0.339	0.252	0.952
At delivery						
Vitamin B12 (pmol/L)	176.0 (80.0)	159.0 (101.0)	205.0 (90.5)	0.144	0.033	0.461
Holo-TC (pmol/L)	28.1 (29.5)	24.6 (22.5)	31.2 (45.6)	0.312	0.075	0.359
Folate (nmol/L)	30.1 (40.6)	43.5 (49.7)	33.6 (53.0)	0.576	0.805	0.988
Homocysteine (μmole/L)	7.8 (8.0)	8.9 (4.2)	8.6 (3.8)	0.307	0.324	0.852
Neonatal characteristics						
Anthropometry						
Birth weight (gms)	2951 (564)	2760 (310)	2778 (388)	0.305	0.601	0.083
Birth length (cm)	48.2 (2.4)	48.4 (1.8)	48.5 (1.9)	0.597	0.426	0.850
Cord blood biochemistry						
Vitamin B12 (pmol/L)	292.0 (226.0)	282.0 (301.0)	380.5 (442.2)	0.858	0.108	0.154
Holo-TC (pmol/L)	94.7 (94.2)	61.3 (89.2)	121.7 (71.2)	0.634	0.164	0.301
Folate (nmol/L)	47.6 (27.9)	56.9 (35.8)	55.5 (33.1)	0.413	0.671	0.562

Vitamin B2 (pmol/L)	321.0 (100.0)	289.0 (78.0)	304.0 (82.0)	0.401	0.476	0.909
Vitamin B6 (plp) (µg/ml)	32.3 (15.1)	23.4 (19.9)	23.5 (16.2)	0.034	0.622	0.059
Vitamin B6 (pyx) (µg/ml)	5.2 (2.6)	4.1 (1.4)	4.8 (2.7)	0.014	0.154	0.271
Homocysteine (µmole/L)	6.9 (5.0)	7.1 (5.9)	5.6 (3.4)	0.602	0.059	0.143
Cord blood hematology						
Hemoglobin (g/dL)	13.9 (1.4)	13.6 (2.2)	14.8 (1.5)	0.774	0.038	0.048
White blood cell count (*10³/uL)	14.2 (3.5)	14.9 (6.9)	12.9 (6.7)	0.719	0.332	0.493
Red blood cell count (*10⁶/uL)	4.0 (0.6)	3.9 (0.5)	4.4 (0.6)	0.798	0.008	0.036
Platelet count (*10³/uL)	272.5 (62.8)	270.0 (78.0)	245.0 (85.5)	0.439	0.321	0.054

- Note:** IQR: Inter Quartile Range, plp: pyridoxal 5'-phosphate, pyx: pyridoxine ; values represent
- median (IQR); P-values calculated by Mann-Whitey test.

1 **Table 2: List of differentially expressed genes in the two intervention groups (B12+MMN and B12**
2 **alone) with respect to the placebo.**

Gene	Gene name	Chromosomal location	Placebo vs B12+MMN		Placebo vs B12		Function
			log2 FoldChange	padj	log2 FoldChange	padj	
<i>KIF14</i>	kinesin family member 14	1q32.1	-1.069	0.073	-0.589	1	Cell division
<i>CENPF</i>	centromere protein F	1q41	-1.045	0.073	-0.629	1	Tubulin binding
<i>KIF15</i>	kinesin family member 15	3p21.31	-1.049	0.073	-0.544	1	Microtubule binding
<i>NCAPG</i>	non-SMC condensin I complex subunit G	4p15.31	-1.132	0.073	-0.609	1	Chromosome segregation
<i>KIFC1</i>	kinesin family member C1	6p21.32	-1.153	0.073	-0.672	1	Mitotic cell cycle
<i>ESCO2</i>	establishment of sister chromatid cohesion N-acetyltransferase 2	8p21.1	-1.21	0.073	-0.636	1	Chromosome segregation
<i>PBK</i>	PDZ binding kinase	8p21.1	-1.656	0.073	-0.668	1	Mitotic cell cycle (regulation of protein kinase activity)
<i>AC091057.1</i>	NA		-0.92	0.073	-0.313	1	Pseudogene
<i>KNL1</i>	kinetochore scaffold 1	15q15.1	-1.12	0.073	-0.649	1	Chromosome segregation
<i>PRSS21</i>	serine protease 21	16p13.3	-1.101	0.073	-0.77	1	Regulation of testicular germ cell maturation
<i>TUBG1</i>	tubulin gamma 1	17q21.31	-0.894	0.073	-0.79	0.89	Major constituent of microtubules
<i>FAM72B</i>	family with	1p11.2	-1.045	0.073	-0.787	1	Cell growth

	sequence similarity 72 member B						regulation
<i>FAM72C</i>	family with sequence similarity 72 member C	1q21.1	-1.066	0.077	-0.75	1	Cell growth regulation
<i>DDX11L10</i>	DEAD/H-box helicase 11 like 10 (pseudogene)	16p13.3	1.089	0.082	0.016	1	Pseudogene
<i>SHCBP1</i>	SHC binding and spindle associated 1	16q11.2	-0.985	0.082	-0.658	1	Spermatogene sis
<i>CLSPN</i>	claspin	1p34.3	-0.96	0.089	-0.644	1	Anaphase- promoting complex binding
<i>CCNA2</i>	cyclin A2	4q27	-1.015	0.093	-0.598	1	Mitotic cell cycle
<i>CDKN3</i>	cyclin dependent kinase inhibitor 3	14q22.2	-1.052	0.093	-0.357	1	Mitotic cell cycle phase transition
<i>PLK1</i>	polo like kinase 1	16p12.2	-1.155	0.093	-0.815	1	Microtubule binding
<i>SKA1</i>	spindle and kinetochore associated complex subunit 1	18q21.1	-1.313	0.093	-0.825	1	Chromosome segregation
<i>NCAPG2</i>	non-SMC condensin II complex subunit G2	7q36.3	-0.74	0.099	-0.428	1	Chromosome segregation
<i>DEPDC1</i>	DEP domain containing 1	1p31.3	-1.179	0.099	-0.54	1	Transcriptional regulation as a transcriptional co-repressor

1 **Figure legends:**

2 **Figure 1: The Pune Maternal Nutrition Study (PMNS) and the Pune Rural Intervention in Young**
 3 **Adolescents (PRIYA) trial.** A) Broad plan of the study. B) CONSORT diagram of the PRIYA trial.

4 **Figure 2: Serial micronutrient levels in PRIYA trial.** Median concentrations of A) vitamin B12
 5 (pmol/L), B) Holo-TC (pmol/L), C) folate (nmol/L), and D) total homocysteine (μmol/L) at baseline (17
 6 years of age), post-intervention (18 years of age; 6-12 months after starting supplementations), 28
 7 weeks gestation and at delivery in the mothers, and in the cord blood of the baby. P-value denotes
 8 significance of difference from the placebo, using the Mann-Whitney test; MMN, multiple
 9 micronutrients.

10 **Figure 3: Gene enrichment analysis of genes differentially expressed between B12+MMN group**
 11 **and placebo.** A) Volcano plot, B) Gene enrichment analysis, C) Clustering analysis of the top 20
 12 differentially expressed genes, and D) Expression plot of *CLSPN*, a negative regulator of cell cycle
 13 progression, in the three intervention groups; MMN, multiple micronutrients.

Figure 1

Figure 2

Figure 3

A

B

C

D